

~~amount of biologically active chemokine.~~

6. (Amended) A method of producing a substantial amount of biologically active chemokine which comprises inserting at least one chemokine gene into a Sendai virus vector, allowing the vector to produce said chemokine, and recovering said chemokine.

9. (Amended) A method of treating human immunodeficiency virus infection, which comprises administering to human subjects a recombinant Sendai virus vector expressing a substantial amount of biologically active CXC-chemokine and allowing the vector to express the chemokine *in vivo*.

10. (Amended) A method of treating human immunodeficiency virus infection, which comprises collecting target cells from human subjects, infecting the cells with a recombinant Sendai virus vector expressing a substantial amount of biologically active CXC-chemokine, and giving the infected cells back to the human subjects.

11. (Amended) A pharmaceutical composition comprising a recombinant Sendai virus vector expressing a substantial amount of biologically active stromal cell-derived factor α or stromal cell-derived factor β and a pharmaceutically acceptable

carrier, wherein said vector is disseminative.

12. (Amended) A pharmaceutical composition comprising a recombinant Sendai virus vector expressing a substantial amount of biologically active stromal cell-derived factor α or stromal cell-derived factor β and a pharmaceutically acceptable carrier, wherein said vector is infectious and replicates autonomously, but is not disseminative.

14. (Amended) A host cell transfected with a recombinant Sendai virus vector expressing a substantial amount of biologically active chemokine.

15. (Amended) A method of inhibiting HIV proliferation which comprises, incubating the host cell of claim 14 in vitro to allow [chemokine] secretion of a substantial amount of biologically active chemokine; and contacting said chemokine with cells that are infected with HIV.

Support for the Amendments

Claims 1, 6, 9, 10, 11, 12, 13 14, and 15 have been amended to require a “substantial amount of biologically active” chemokine. Support for these amendments can be found in the specification in Example 2, pages 10-11 which states that “substantial